LIVZON PHARMA (01513) shares rose nearly 3% during trading, last up 2.55% at HK$20.90, with turnover reaching HK$15.2846 million.

According to a recent announcement on LIVZON PHARMA's official WeChat account, the company's first innovative biologic in China targeting the IL-17A/F dual pathway, Libeitan® (generic name: Leikangchita monoclonal antibody injection), has officially received market approval.

Guosen Securities noted that Leikangchita (an IL-17A/F antibody) demonstrated superior efficacy compared head-to-head with secukinumab in the treatment of psoriasis, and the Phase 3 clinical trial for ankylosing spondylitis has also yielded favorable results.